VEGF: Potential therapy for renal regeneration.
VEGF: Potential therapy for renal regeneration.
复制标题
DOI：
10.3410/m4-1
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Chade AR
中科院分区：
文献类型：
--
作者：
Chade AR
血管内皮生长因子（VEGF）在血管生成中起着重要作用。许多研究集中在其在健康和疾病中的作用，并讨论了VEGF作为治疗工具和靶点的可能性，这是基于其对血管增殖和细胞存活的特异性作用。一方面，抗VEGF疗法处于许多实体瘤治疗的最前沿，但VEGF的阻断会产生附带效应，如高血压和肾损伤，这主要是由于微血管系统的异常。另一方面，最近的临床和实验证据已经显示了使用VEGF施用通过刺激微血管增殖和修复来保护缺血组织如心肌或肾的可行性。在这篇评论中，我们讨论了使用肾内注射VEGF来保护肾脏微循环的可能性和潜在机制，从而减少慢性肾血管疾病的进行性肾损伤。VEGF的靶向给药可能构成一种新的独立或辅助干预，有可能成为保护肾功能的综合计划的一部分。
Vascular endothelial growth factor (VEGF) plays a central role in angiogenesis. A number of studies have focused on its role in health and disease and discussed the possibility of VEGF as both a therapeutic tool and target based on its specific actions on vascular proliferation and cell survival. On one side, anti-VEGF therapies are at the fore-front of treatment of many solid tumors, but blockade of VEGF carries collateral effects such as hypertension and renal damage largely due to abnormalities in the microvasculature. On the other hand, recent clinical and experimental evidence has shown the feasibility of using VEGF administration to protect ischemic tissues such as the myocardium or the kidney via stimulation of microvascular proliferation and repair. In this commentary, we discuss the possibility and potential mechanisms of using intra-renal administration of VEGF to preserve the renal microcirculation and, consequently, decrease progressive renal injury in chronic renovascular disease. Targeted administration of VEGF may constitute a novel stand-alone or co-adjuvant intervention with the potential to become a part of a comprehensive plan to protect renal function.